Compare Orchid Pharma with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs ALEMBIC - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA ALEMBIC ORCHID PHARMA/
ALEMBIC
 
P/E (TTM) x -87.8 60.1 - View Chart
P/BV x 25.2 5.2 485.8% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ORCHID PHARMA   ALEMBIC
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
ALEMBIC
Mar-18
ORCHID PHARMA/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs19472 269.4%   
Low Rs3534 103.2%   
Sales per share (Unadj.) Rs276.54.7 5,881.5%  
Earnings per share (Unadj.) Rs-79.26.1 -1,297.7%  
Cash flow per share (Unadj.) Rs-43.56.2 -695.7%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.940.7 132.7%  
Shares outstanding (eoy) m70.45267.03 26.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.411.3 3.7%   
Avg P/E ratio x-1.48.7 -16.7%  
P/CF ratio (eoy) x-2.68.5 -31.1%  
Price / Book Value ratio x2.11.3 163.0%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m8,06714,139 57.1%   
No. of employees `0002.8NA-   
Total wages/salary Rs m2,527207 1,218.4%   
Avg. sales/employee Rs Th6,956.1NM-  
Avg. wages/employee Rs Th902.5NM-  
Avg. net profit/employee Rs Th-1,993.0NM-  
INCOME DATA
Net Sales Rs m19,4771,255 1,551.7%  
Other income Rs m407370 110.0%   
Total revenues Rs m19,8841,625 1,223.3%   
Gross profit Rs m1,103111 992.4%  
Depreciation Rs m2,51938 6,664.6%   
Interest Rs m5,2272 307,458.8%   
Profit before tax Rs m-6,236442 -1,411.5%   
Minority Interest Rs m200-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-12524 -522.8%   
Profit after tax Rs m-5,5801,630 -342.4%  
Gross profit margin %5.78.9 64.0%  
Effective tax rate %2.05.4 37.0%   
Net profit margin %-28.7129.8 -22.1%  
BALANCE SHEET DATA
Current assets Rs m11,0141,867 589.9%   
Current liabilities Rs m32,060591 5,422.9%   
Net working cap to sales %-108.1101.6 -106.3%  
Current ratio x0.33.2 10.9%  
Inventory Days Days9594 100.7%  
Debtors Days Days3474 45.6%  
Net fixed assets Rs m29,4401,791 1,643.9%   
Share capital Rs m705534 131.9%   
"Free" reserves Rs m2,04310,324 19.8%   
Net worth Rs m3,80010,858 35.0%   
Long term debt Rs m9,01841 21,888.1%   
Total assets Rs m46,51011,591 401.3%  
Interest coverage x-0.2260.9 -0.1%   
Debt to equity ratio x2.40 62,542.3%  
Sales to assets ratio x0.40.1 386.7%   
Return on assets %-0.814.1 -5.4%  
Return on equity %-146.915.0 -978.3%  
Return on capital %-3.715.2 -24.6%  
Exports to sales %37.91.5 2,450.8%   
Imports to sales %22.621.0 107.8%   
Exports (fob) Rs m7,37819 38,028.9%   
Imports (cif) Rs m4,406263 1,673.2%   
Fx inflow Rs m7,51319 38,728.4%   
Fx outflow Rs m5,649264 2,141.2%   
Net fx Rs m1,865-244 -762.8%   
CASH FLOW
From Operations Rs m1,682236 713.2%  
From Investments Rs m-9,860-224 4,402.0%  
From Financial Activity Rs m6,644-27 -24,976.7%  
Net Cashflow Rs m-1,535-15 10,371.6%  

Share Holding

Indian Promoters % 32.3 64.0 50.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 0.2 2,300.0%  
FIIs % 3.3 9.7 34.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 26.1 211.9%  
Shareholders   84,811 54,701 155.0%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   NEULAND LABS  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  WYETH  

Compare ORCHID PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 598 Points Lower, Nifty Settles Below 15,100-Mark; HDFC and JSW Steel Top Losers(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day deep in the red.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


Mar 4, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA 8-QTR ANALYSIS

COMPARE ORCHID PHARMA WITH

MARKET STATS